Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Liabilities and Shareholders Equity (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Liabilities and Shareholders Equity data on record, last reported at $10.4 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 17.05% year-over-year to $10.4 million; the TTM value through Sep 2025 reached $39.2 million, down 10.28%, while the annual FY2024 figure was $9.6 million, 28.41% down from the prior year.
  • Liabilities and Shareholders Equity reached $10.4 million in Q3 2025 per CYCN's latest filing, up from $9.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $100.0 million in Q1 2021 and bottomed at $8.9 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $28.8 million, with a median of $13.4 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 75.38% in 2023, then grew 17.05% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $59.3 million in 2021, then crashed by 69.53% to $18.1 million in 2022, then fell by 26.02% to $13.4 million in 2023, then decreased by 28.41% to $9.6 million in 2024, then increased by 8.77% to $10.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $10.4 million in Q3 2025, $9.4 million in Q2 2025, and $9.8 million in Q1 2025.